PHARMA BULLETIN ⚕️

PHARMA UPDATES⚕️
(1)Bharat Biotech’s ROTAVAC 5D receives WHO pre-qualification.
It's the only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume.
Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D. The new variant of ROTAVAC, ROTAVAC 5D, is a rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children, the company said in a statement.
(2)Glenmark inks agreement with SaNOtize to commercialise nasal spray for COVID-19 treatment in India and other Asian markets
Nitric oxide (NO) has anti-microbial properties with a direct proven effect on SARS-CoV-2.
Glenmark Pharmaceuticals and SaNOtize Research & Development have announced an exclusive long-term strategic partnership to manufacture, market and distribute its Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets, including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam, a statement from Glenmark said.
(3)Achieving Aatmanirbharta in APIs: Are we on the right track?
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats.
For the last two decades, the Indian pharmaceutical industry has been growing almost 1.5 times the Indian GDP. The current government has an aggressive plan of amplifying the industry size from $41 billion to almost $120-150 billion in 2030. Globally, India has benchmarked its position in formulation development and manufacturing. However, India’s dependence on China (primarily) and a few other countries for importing active pharma ingredients (APIs) to manufacture drugs is a problem that looms large in the Indian pharma sector’s path to progress.
(4)India and UK to conduct clinical trials of Ashwagandha for promoting COVID-19 recovery.
MoU signed between All India Institute of Ayurveda (under the Ministry of Ayush) and the UK’s London School of Hygiene and Tropical Medicine.
The Ministry of Ayush has collaborated with the UK’s London School of Hygiene and Tropical Medicine (LSHTM) to conduct a study on Ashwagandha for promoting recovery from COVID-19, a statement has said.
(5)Takeda and Frazier Healthcare Partners collaborate to develop clinical-stage norovirus vaccine candidate.
Takeda will focus its efforts on dengue, zika and pandemic vaccines.
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate. Takeda has granted a licence to HilleVax for the exclusive development and commercialisation rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan, the company said in a statement.

Comments

Post a Comment

Popular posts from this blog

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1.Zydus vaccine for children above 12 years could be available by August. National technical advisory board group of Immunisation ( NTAGI ) chairman Dr Arora also added that the trials are likely to be Completed by the end of next month. 2.India achieve milestone of conducting 40 crores Covid sample testing. India has tested 40,18,11,892 samples across the nation till 25 June 2021 The Indian council of Medical Research said. 251 doctors Challenge Govt. FIR Diktat. -Ahmedabad: A group of 251 graduate students and super-specialists practicing in Gujarat approach the Gujarat High Court to challenge the decision of the state government to join Covid-19’s obligations and call for obligations. I submitted a FIR as not responding. 4. Serum institute of India produce more than 10 crore Doses of covishield in June. The Drugs Controller General of India (DCGI) on Sunday said that the Serum Institute of India has produced 10 crore
Read more

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1. Covid 19 Vaccine effective for at least 1 year :- Karnataka Virologist. Karnataka based Virologist Dr V Ravi said that available evidence suggests that vaccinated person would get protection for two to three years If more troubling Variants don't emerge. 2.Indian Immunologicals to begin Drug substance production for Covaxin from June. Indian Immunological Limited has announced it's plan to start the production of drug substance for Covaxin From June and Despatch the first Batch to Bharat Biotech by July. 3. Zydus Cadilla plans test for its Covid Vaccine in 5 to 12 years age group. Zydus Cadilla is planning to start Clinical trials of its Covid Vaccine, ZycoV-D, in children of 5 to 12 years age group. 4. Modern laboratories to mfg. Amphotericin B. Amphotericin B is Used for treatment of Black Fungus, White Fungus and Yellow Fungus. 5.IIT Hyderabad researchers develop oral an solution to treat black
Read more

PHARMA BULLETIN⚕️

Image
PHARMA UPDATES ⚕️ 1.BDR Pharma launches drug to treat advances tage Ovarian and Prostate Cancer. BDR Pharma has launched Rucaparib under brand name BDPARIB. It first affordable drug treat Ovarian and Prostate Cancer. 2.Seeking Pills to cure Covid Pharma Companies eye alternative to vaccine. Many drug makers are working on so called oral antivirals which would copy what drug Tamiflu does for Influenza. 3.Lupin gets $50 Million from Boehringer for anticancer drug. Lupin has received payment of around Rs.363.5 Crore from Boehringer Ingelheim for achievement of key milestones by its cancer drug potential drug therapy for cancer patients. 4.Agrrement signed b/w Bharat Biotech Gujarat Covid Vaccine Consortium. Memorandum of understanding (MoU) has signed b/w Bharat Biotech and Gujarat Covid Vaccine Consortium for contract Mfg.drug substance for Covaxin. 5.Zydus Cadilla has sought drugs Controller General of India (DCGI)  Approval to
Read more